Brookline Capital Acquisition Corp II

Brookline Capital Acquisition Corp II

Brookline Capital Acquisition Corp II formed in 2020 as a special purpose acquisition company led by CEO Samuel Levitt and CFO Patrick Sturgeon. It followed the first Brookline Capital Acquisition Corp, which merged with Apexigen in 2022. The SPAC emerged from the Brookline Capital Markets ecosystem, a New York-based investment bank focused on healthcare. The firm filed to raise $130 million and upsized to $149.5 million, pricing its IPO in October 2020 with units listed on Nasdaq. The vehicle aimed to identify a merger target in the healthcare industry, consistent with the advisory firm's sector expertise. Brookline Capital Markets, the sponsor's affiliate, executes public offerings and private placements for biotech and life sciences companies. SPAC II's trust held approximately $150 million at the time of IPO. The SPAC did not announce a definitive merger agreement during its active search window. Its liquidation followed the broader SPAC market correction, where a record number of vehicles failed to complete combinations as regulatory scrutiny increased and redemption rates spiked. In January 2023, Brookline Capital Acquisition Corp II announced it would liquidate and return trust funds to shareholders, ceasing operations. The SPAC redeemed all outstanding shares at approximately $10.46 per share. The dissolution reflected the post-2020 environment where capital returned to investors became the rational path for hundreds of SPACs that could not secure viable targets. Brookline Capital Markets continues to operate as a healthcare-focused investment bank. The SPAC operated as a single-purpose capital pool with a 24-month deadline — a structure that proved vulnerable when deal flow dried up after the speculative SPAC cycle peaked in 2021. Unlike permanent-capital private funds, the vehicle's forced liquidation timeline left no option but dissolution when target economics and sponsor economics failed to align.